Akershus University Hospital is a Norwegian public university hospital in the Greater Oslo Region. It is located in the Lørenskog municipality in the region of Viken, northeast of the Norwegian capital Oslo.

There are 953 beds in Akershus universitetssykehus HF.

During the past decade, Akershus universitetssykehus HF conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 9 clinical trials were completed, i.e. on average, 24.3% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 8 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Akershus universitetssykehus HF" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Oslo University Hospital" with 5 trials sponsored, "Norwegian University of Science and Technology" with 4 trials sponsored and "University Hospital, Akershus" with 4 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Akershus universitetssykehus HF" #1 collaborator was "St. Olavs Hospital" with 6 trials as a collaborator, "University Hospital, Akershus" with 6 trials as a collaborator, "Haukeland University Hospital" with 5 trials as a collaborator, "Helse Stavanger HF" with 5 trials as a collaborator and "University Hospital of North Norway" with 5 trials as a collaborator. Other collaborators include 101 different institutions and companies that were collaborators in the rest 83 trials.

According to Clinical.Site data, the most researched conditions in "Akershus universitetssykehus HF" are "Crohn's Disease" (4 trials), "Ulcerative Colitis" (4 trials), "Chronic Kidney Disease" (2 trials), "Colitis, Ulcerative" (2 trials) and "Crohn Disease" (2 trials). Many other conditions were trialed in "Akershus universitetssykehus HF" in a lesser frequency.

Most popular intervention types in "Akershus universitetssykehus HF" are "Drug" (33 trials), "Other" (4 trials), "Behavioral" (2 trials), "Biological" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Atezolizumab" (3 trials), "Carboplatin" (2 trials), "Empagliflozin" (2 trials) and "Etrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Akershus universitetssykehus HF" are 41 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Akershus universitetssykehus HF". undefined are not yet recruiting, 11 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Akershus universitetssykehus HF, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Akershus universitetssykehus HF, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".